Inhaled pharmacotherapy and stroke risk in patients with chronic obstructive pulmonary disease: A nationwide population based study using two-stage approach

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Lin, Hui Wen ^a   Chung, Chi Li ^b,c   Lin, You Shuei ^d   Yu, Chia Ming ^c   Lee, Chun Nin ^b,e,f   Bien, Mauo Ying ^b,c,e  

^a SOOCHOW UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FENOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; IPRATROPIUM BROMIDE; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; SALBUTAMOL SULFATE; SALMETEROL; SHORT ACTING DRUG; TERBUTALINE SULFATE; TIOTROPIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; RISK ASSESSMENT; RISK REDUCTION; COMBINATION DRUG THERAPY; FACTUAL DATABASE; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK; STROKE; SURVIVAL ANALYSIS;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; COHORT STUDIES; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK; STROKE; SURVIVAL ANALYSIS;

EID: 84941331993     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130102     Document Type: Article

References (25)

1. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187: 347-365. doi: 10.1164/rccm.201204-0596PP PMID: 22878278
2. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. (2006) Global burden of COPD: systematic review and meta-analysis. Eur Respir J 28: 523-532. PMID: 16611654
3. Man SF, Van Eeden S, Sin DD. (2012) Vascular risk in chronic obstructive pulmonary disease: role of inflammation and other mediators. Can J Cardiol 28: 653-661. doi: 10.1016/j.cjca.2012.06.013 PMID: 22902150
4. Schnell K, Weiss CO, Lee T, Krishnan JA, Leff B, Wolff JL, et al. (2012) The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med 12: 26. doi: 10.1186/1471-2466-12-26 PMID: 22695054
5. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. (2010) Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 65: 956-962. doi: 10.1136/thx.2009.128082 PMID: 20871122
6. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. (2010) Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 137: 1091-1097. doi: 10.1378/chest.09-2029 PMID: 20022970
7. Gross NJ. (2012) Novel antiinflammatory therapies for COPD. Chest 142: 1300-1307. doi: 10.1378/ chest.11-2766 PMID: 23131938
8. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356: 775-789. PMID: 17314337
9. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359: 1543-1554. doi: 10.1056/ NEJMoa0805800 PMID: 18836213
10. National Health Insurance Research Database, Taiwan. Available: http://nhird.nhri.org.tw/en/index.htm
11. Guo YH, Lin HY, Lin LL, Cheng CY. (2012) Self-reported myopia in Taiwan: 2005 Taiwan National Health Interview Survey. Eye 26: 684-689. doi: 10.1038/eye.2012.9 PMID: 22344187
12. Suissa S. (2012) Randomized Trials Built on Sand: Examples from COPD, Hormone Therapy, and Cancer. Rambam Maimonides Med J. 31: e0014 doi: 10.5041/RMMJ.10082 PMID: 23908838
13. Lin HW, Chen YH. (2014) Adjustment for missing confounders in studies based on observational databases: Two-stage calibration combining propensity scores from primary and validation data. Am J of Epidemiol 180: 308-317. doi: 10.1093/aje/kwu130 PMID: 24966224
14. Stürmer T, Schneeweiss S, Avorn J, Glynn RJ. (2005) Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol 162: 279-289. PMID: 15987725
15. Lin HW, Chen YH. (2010) Association analysis under population stratification: a two-stage procedure utilizing population- and family-based analyses. Hum Hered 69: 160-170. doi: 10.1159/000267996 PMID: 20029228
16. Rosner B, Spiegelman D, Willett WC. (1990) Correction of logistic regression relative risk estimates and confidence intervals for measurement error: The case of multiple covariates measured with error. Am J Epidemiol 132: 734-745. PMID: 2403114
17. Van Eeden S, Leipsic J, Paul Man SF, Sin DD. (2012) The relationship between lung inflammation and cardiovascular disease. Am J Respir Crit Care Med 186: 11-16. doi: 10.1164/rccm.201203-0455PP PMID: 22538803
18. Sinden NJ, Stockley RA. (2010) Systemic inflammation and comorbidity in COPD: a result of 'overspill' of inflammatory mediators from the lungs? Review of the evidence. Thorax 65: 930-936. doi: 10.1136/ thx.2009.130260 PMID: 20627907
19. Cook D, Guyatt G, Wong E, Goldstein R, Bedard M, Austin P, et al. (2001) Regular versus as-needed short-acting inhaled β-agonist therapy for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163: 85-90. PMID: 11208630
20. Salpeter SR, Ormiston TM, Salpeter EE. (2004) Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 125: 2309-2321. PMID: 15189956
21. Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. (2012) Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest 142: 305-311. doi: 10. 1378/chest.11-1597 PMID: 22871756
22. Varela S, Mendez J, González de la Cuesta C, Iglesias I, González C, et al. (2009) Cardiovascular disease risk associated with asthma and respiratory morbidity might be mediated by short-acting β2-agonists. J Investig Allergol Clin Immunol 123: 124-130.
23. Pinto-Plata VM, Müllerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Celli BR. (2006) C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 61: 23-28. PMID: 16143583
24. Man SF, Sin DD. (2005) Effects of corticosteroids on systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2: 78-82. PMID: 16113473
25. Sin DD, Man SF, Marciniuk DD, Ford G, FitzGerald M, Wong E, et al. (2008) The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177: 1207-1214. doi: 10.1164/rccm.200709-1356OC PMID: 18310480